Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-17

Clinical Trial Update: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Status: RECRUITING